Growth recognition biomodal is recognized for rapid growth as part of The Sunday Times 100 Tech 2026, signaling strong market momentum and a compelling case for customers and partners seeking proven scaling capabilities in omics analytics.

Multiomics leadership The duet multiomics platform combines genetic and epigenetic data from low input samples, presenting a unique value proposition for oncology, neurodegeneration, and aging research—markets with high demand for integrated molecular insights and streamlined workflows.

Recent integrations Recent announcements show compatibility with Element Biosciences AVITI instruments and new DNA testing workflows, suggesting cross-vendor collaboration opportunities and potential for co-marketing or bundled offerings with sequencing providers.

Financing health With substantial funding and revenue currently in the low-to-mid multi-million range, biomodal demonstrates financial backing and scale potential that can support enterprise deployments, longer-term service agreements, and investment in expansion projects.

Tech footprint A modern tech stack including AWS, Azure, Kubernetes, Terraform and GitHub indicates robust cloud-native capabilities that can align with enterprise customers’ IT and data governance requirements, enabling upsell to large labs seeking scalable analytics platforms.